Clinical Trials Logo

Social Anxiety clinical trials

View clinical trials related to Social Anxiety.

Filter by:

NCT ID: NCT01376596 Completed - Schizophrenia Clinical Trials

Group Cognitive-behavioral Intervention for Social Anxiety in Schizophrenia

Start date: August 2011
Phase: Phase 1/Phase 2
Study type: Interventional

This study will explore the helpfulness of a short psychological group treatment called cognitive-behavioral therapy, or CBT. CBT is a form of therapy that is very structured and it aims to improve difficulties that are related to behaviors and emotions by first working on identifying and changing negative inaccurate thoughts. The main goal of this intervention is to see if group CBT reduces the symptoms of social anxiety in people with schizophrenia so that they can improve their social functioning and help their psychotic symptoms. The study compares the usefulness of adding CBT to standard services.

NCT ID: NCT00884897 Completed - Social Anxiety Clinical Trials

Oxytocin and Social Cognition in Schizophrenia

Start date: January 2010
Phase: Phase 2
Study type: Interventional

Objective: Social Cognition and Emotional Intelligence have been shown to be deficient in patients with schizophrenia and these are not remediated by antipsychotic medications or psychosocial interventions. Social cognition is associated with functional outcome, an important step in striving for recovery in this population. The hormone and neurotransmitter, oxytocin, which has been associated with social bonding and trust has been shown to improve measures of some aspects of social cognition in humans. The study will assess the effect of acute administration of intranasal oxytocin on measures of social cognition and functioning as well as on emotional intelligence and symptoms. Study population: The study population will include patients with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder who have been on a stable medication regimen for 6 weeks. We will enroll a total of 30 subjects (N=15 placebo and N=15 oxytocin groups). Experimental design and methods: After a one week lead in phase, participants will undergo 3 weeks of oxytocin (20 IU BID) or placebo administration (double blind) in addition to their existing medication regimen. Outcome measures will be administered during the lead in phase, and at the end of the study drug administration phase (under the acute effect of OT). The primary outcome measure will be the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) and the Maryland Assessment of Social Competence (MASC). Secondary measures include rating from the domains of social cognition (emotion perception, attributional style, theory of mind and social perception), symptom rating and measures of social anxiety and quality of life. Side effects and symptoms will be measured weekly.

NCT ID: NCT00872118 Completed - Alcohol Consumption Clinical Trials

Brief Intervention for Socially Anxious College Drinkers

BISAD
Start date: April 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to develop and test a new brief intervention to reduce heavy drinking and social anxiety in college drinkers.